Madopar

Levodopa and Benserazide, the active ingredient in Madopar, is a dopamine precursor and dopa decarboxylase inhibitor presented as an oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adult patients who require symptomatic motor control.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑market product.

Madopar is used in the management of movement disorders that respond to dopaminergic therapy. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: provides symptomatic relief of similar motor deficits. - Secondary parkinsonism: offers clinical benefit when dopamine deficiency contributes to the presentation.

Madopar may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: often occurs early in therapy. - Dizziness or light‑headedness: related to orthostatic changes. - Headache: transient and usually mild. - Insomnia: may affect sleep quality.

Serious or Rare Side Effects: - Dyskinesia: involuntary movements that can be disabling. - Psychiatric disturbances: hallucinations, confusion or depression. - Severe hypotension: sudden drop in blood pressure requiring medical attention. - Allergic reactions: rash, swelling or anaphylaxis in rare cases.

When prescribing Madopar, clinicians should consider several safety measures. - Assess renal function: adjust therapy in severe impairment. - Monitor for dyskinesia: modify dose if excessive movements develop. - Screen psychiatric history: watch for hallucinations or mood changes. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Use with food: may lessen gastrointestinal irritation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Madopar can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Pyridoxine (vitamin B6): reduces levodopa efficacy. - Dopamine‑blocking antipsychotics: diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood‑pressure lowering. - Iron or calcium supplements: can impair levodopa absorption if taken simultaneously.